Pulmonology Xagena
Despite currently available therapies and detailed guidelines, many people with mild asthma remain symptomatic; it is important to establish the efficacy and safety of new treatments in this group. ...
In patients with symptomatic asthma receiving ICS or ICS+LABA, phase III studies have demonstrated improved lung function with Tiotropium ( Spiriva ) Respimat, a once-daily long-acting anticholinergic ...
Once-daily Tiotropium ( Spiriva ) Respimat, a long-acting anticholinergic bronchodilator, has been shown in a phase III program to improve lung function and reduce severe exacerbation risk in severe a ...
